Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

226.65 +0.49 (+0.21%)
Streaming Delayed Price Updated: 9:39 AM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
From Johnson & Johnson
Via Business Wire
News headline image
3 Giant Dividend Stocks Raising Payouts With Yields Up to 4% ↗
Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025. 
Via MarketBeat
News headline image
Could This Healthcare Stock Help Make You Rich Over the Next Decade? ↗
Intuitive Surgical has already made many of its early investors wealthy. 
Via The Motley Fool
News headline image
Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report? ↗
Solid results weren't impressive enough to move the stock price higher. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗
This once-beaten-down pharma stock remains an intriguing turnaround story. 
Via The Motley Fool
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
These companies boast significant upside potential. 
Via The Motley Fool
News headline image
This "Boring" Dividend King Is Quietly Turning Into a Growth Machine ↗
The blue chip dividend stock is quietly growing again as a streamlined company. 
Via The Motley Fool
News headline image
3 Healthcare Stocks That Have Held Up in Every Market Downturn ↗
Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns. 
Via The Motley Fool
Topics Economy
News headline image
Skip the 10-Year Bond? 3 Dividend Aristocrats to Consider Now ↗
Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation 
Via MarketBeat
Topics Bonds Earnings Economy
News headline image
The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson ↗
MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data. 
Via Benzinga
News headline image
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results ↗
Johnson & Johnson (NYSE:JNJ) reports upbeat earnings for Q1, with higher sales and raised fiscal 2026 guidance. Some analysts raise price targets. 
Via Benzinga
News headline image
Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst ↗
Johnson & Johnson reports strong Q1, beating expectations and setting the stage for future growth. Analysts maintain Buy rating. 
Via Benzinga
News headline image
Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately... 
Via MarketMinute
Topics Economy
News headline image
Transcript: Johnson & Johnson Q1 2026 Earnings Conference Call ↗
 
Via Benzinga
News headline image
Oil Drops, Dimon Warns, and the Record Is Within Reach ↗
Within 0.2% of its January all-time high. That's where the S&P 500 closed on Tuesday, not quite there yet, but close enough that the question investors are asking has quietly shifted from "when does... 
Via Chartmill
Topics Artificial Intelligence Economy Government
News headline image
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
What Makes a Healthcare Stock Worth Holding Through a Recession? ↗
Not all healthcare stocks are defensive in a downturn. Here's what to consider. 
Via The Motley Fool
Topics Economy
News headline image
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results ↗
Via MarketBeat
News headline image
Johnson & Johnson Q1 2026 Earnings Call Transcript ↗
Johnson & Johnson (NASDAQ: JNJ) reported first-quarter financial results on Tuesday. The transcript from the company's first-quarter earnings call has been provided below. 
Via Benzinga
Topics Earnings
News headline image
Johnson & Johnson Shatters Expectations in Q1 2026, Raising Full-Year Outlook as Healthcare Giant Pushes Toward $100 Billion Milestone
NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Johnson & Johnson Q1 Performance: Cancer Drug Revenue Grows, Free Cash Flow Falls, Hikes Dividend ↗
Johnson & Johnson Q1 pharma growth offsets immunology decline; company raises guidance and extends dividend streak. 
Via Benzinga
News headline image
The New J&J: A 2026 Deep Dive into the Global Healthcare Titan
As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue,... 
Via Finterra
Topics Artificial Intelligence Death Economy
News headline image
Dow Jones' J&J Slips Despite Beating First-Quarter Calls, Hiking Guidance ↗
Johnson & Johnson stock fell early Tuesday despite better-than-expected first-quarter sales and earnings, and a guidance hike. 
Via Investor's Business Daily
Topics Stocks
News headline image
Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports ↗
Four of the 30 Dow Jones Industrial Average stocks report this week. Here's a look at the companies and what the key figures to watch are. 
Via Benzinga
Topics Stocks
News headline image
Is This Dividend King With a 63-Year Dividend Streak A Buy Before April 14?
This Dividend King offers a rare mix of safety and upside heading into earnings. 
Via Barchart.com
News headline image
Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗
Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.